Archivio istituzionale della ricerca dell'Università degli Studi di Palermo

SIRAGUSA, Sergio
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 15.652
EU - Europa 6.239
AS - Asia 2.221
AF - Africa 78
SA - Sud America 20
OC - Oceania 11
Continente sconosciuto - Info sul continente non disponibili 10
Totale 24.231
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 15.589
IT - Italia 2.239
CN - Cina 1.074
UA - Ucraina 890
SG - Singapore 795
DE - Germania 787
FI - Finlandia 747
IE - Irlanda 350
GB - Regno Unito 314
SE - Svezia 242
RU - Federazione Russa 174
FR - Francia 152
IN - India 76
RO - Romania 76
BE - Belgio 71
KR - Corea 69
CI - Costa d'Avorio 65
CA - Canada 58
TR - Turchia 51
HK - Hong Kong 36
NL - Olanda 36
PL - Polonia 36
CH - Svizzera 33
IR - Iran 32
ES - Italia 21
AT - Austria 20
GR - Grecia 20
PK - Pakistan 19
BR - Brasile 15
ID - Indonesia 13
UZ - Uzbekistan 11
CZ - Repubblica Ceca 10
EU - Europa 8
LB - Libano 7
AU - Australia 6
NZ - Nuova Zelanda 5
IQ - Iraq 4
JP - Giappone 4
BD - Bangladesh 3
BG - Bulgaria 3
CO - Colombia 3
DZ - Algeria 3
MY - Malesia 3
PH - Filippine 3
SA - Arabia Saudita 3
TW - Taiwan 3
VN - Vietnam 3
ZA - Sudafrica 3
A2 - ???statistics.table.value.countryCode.A2??? 2
EE - Estonia 2
ET - Etiopia 2
HR - Croazia 2
HU - Ungheria 2
IL - Israele 2
KW - Kuwait 2
KZ - Kazakistan 2
MA - Marocco 2
MD - Moldavia 2
MM - Myanmar 2
MX - Messico 2
AE - Emirati Arabi Uniti 1
AL - Albania 1
AO - Angola 1
CL - Cile 1
CR - Costa Rica 1
DK - Danimarca 1
EC - Ecuador 1
EG - Egitto 1
KH - Cambogia 1
LT - Lituania 1
LU - Lussemburgo 1
LV - Lettonia 1
LY - Libia 1
NO - Norvegia 1
PA - Panama 1
PR - Porto Rico 1
PT - Portogallo 1
QA - Qatar 1
RS - Serbia 1
SI - Slovenia 1
SK - Slovacchia (Repubblica Slovacca) 1
TH - Thailandia 1
Totale 24.231
Salva come PNG Salva come JPEG
Città #
Fairfield 2.383
Ashburn 1.563
Chandler 1.248
Woodbridge 1.246
Houston 1.189
Wilmington 993
Seattle 896
Cambridge 755
Singapore 640
Ann Arbor 633
Jacksonville 458
Palermo 408
Medford 388
Dublin 349
Des Moines 273
Princeton 255
Altamura 251
Nanjing 233
Lawrence 184
San Diego 172
Boardman 146
Dearborn 145
Beijing 137
Tulsa 118
New York 101
Milan 95
Ludwigshafen am Rhein 88
Santa Clara 84
Shenyang 79
Rome 71
Brussels 68
Nanchang 66
Abidjan 64
Hebei 60
Helsinki 59
London 58
Seongnam 56
Tianjin 54
Changsha 47
Jinan 45
Izmir 41
Jiaxing 41
Zhengzhou 41
San Paolo di Civitate 40
Columbus 39
Bremen 38
Falls Church 34
Redwood City 34
Verona 32
Ningbo 31
Kumar 30
Los Angeles 27
Phoenix 27
Washington 27
Saint Petersburg 25
Tehran 25
Guangzhou 24
Venice 24
Duncan 22
Munich 22
Taizhou 21
Montréal 20
Auburn Hills 19
Orange 19
Hangzhou 17
Piscataway 17
San Mateo 17
Hong Kong 16
Kunming 16
Napoli 16
Regensburg 16
San Jose 16
Dallas 15
Kilburn 15
Ottawa 15
Catania 14
Chicago 14
Norwalk 14
Shanghai 14
Stockholm 14
Toronto 13
Frankfurt am Main 12
Haikou 12
Pune 11
Biandronno 10
Lanzhou 10
Moscow 10
Central 9
Hefei 9
Kraków 9
Lappeenranta 9
Redmond 9
Springfield 9
Torino 9
Turin 9
Bologna 8
Hounslow 8
Marigliano 8
Sandston 8
Sciara 8
Totale 17.297
Salva come PNG Salva come JPEG
Nome #
Curva da carico orale di metionina nella valutazione di pazienti affetti da patologia trombotica 546
Absolute Lymphocyte Count Is Unrelated to Overall Survival in Newly Diagnosed Elderly Patients with Multiple Myeloma Treated with Immunomodulatory Drugs. 348
Clinical phenotype and response to different lines of therapy in elderly with immune thrombocytopenia: A retrospective study 263
null 231
Peripheral circulating cells with paroxysmal nocturnal haemoglobinuria phenotype after a first episode of cerebral sinus vein thrombosis: Results from a multicentre cross-sectional study 201
Efficacy of ruxolitinib retreatment in a patient with high-risk myelofibrosis using the international prognostic scoring system 194
Cardiovascular risk in polycythemia vera: Thrombotic risk and survival: Can cytoreductive therapy be useful in patients with low-risk polycythemia vera with cardiovascular risk factors? 187
Comparison between thrombotic risk scores in Essential Thrombocythemia and survival implications 183
Residual vein thrombosis for assessing duration of anticoagulation after unprovoked deep vein thrombosis of the lower limbs: the extended DACUS study. 178
EGFR genomic alterations in cancer: prognostic and predictive values 175
Home therapy for deep vein thrombosis and pulmonary embolism in cancer patients 173
Successful Treatment of Gastrointestinal Bleeding With Recombinant Factor VIIa After Kidney Transplantation in Patients With Pancytopenia. 171
Late onset of unilateral optic disk edema secondary to treatment with imatinib mesylate 169
Bleeding Prophylaxis in a Child With Cleft Palate and Factor VII Deficiency: A Case Report 168
Incidence of thromboembolic complications in patients with atrial fibrillation or mechanical heart valves with a subtherapeutic international normalized ratio: a prospective multicenter cohort study 161
Hematopoietic peripheral circulating blood stem cells as an independent marker of good transfusion management in patients with β-thalassemia: results from a preliminary study 156
Acquired haemophilia in cancer: A systematic and critical literature review 155
Incidence of venous thromboembolism and use of anticoagulation in hematological malignancies: Critical review of the literature 155
Health-related quality of life and psychological well-being in elderly patients with haemophilia 154
Low molecular weight heparins in cancer patients: to treat thromboembolic events, the tumor, of both? 152
Gastrointestinal bleeding due to angiodysplasia in patients with type 1 von Willebrand disease: report on association and management 152
Hemorheological parameters in Monoclonal Gammopathy of Undetermined Significance (MGUS) 152
The incidence of heparin-induced thrombocytopenia in medical patients treated with low-molecular-weight heparin: a prospective cohort study 150
Iron-dependent erythropoiesis in women with excessive menstrual blood losses and women with normal menses 149
Role of clinical and laboratory parameters for treatment choice in patients with inherited FVII deficiency undergoing surgical procedures: evidence from the STER registry 149
Immunosenescence and lymphomagenesis 148
Optimal Duration of Low Molecular Weight Heparin for the Treatment of Cancer-Related Deep Vein Thrombosis: The Cancer-DACUS Study. 147
Activated prothrombin complex concentrate (FEIBA®) in acquired haemophilia A: a large multicentre Italian study - the FAIR Registry 147
Residual vein thrombosis to establish duration of anticoagulation after a first episode of deep vein thrombosis: The Duration of Anticoagulation based on Compression Ultrasonography (DACUS) study 145
Factor VII Deficiency: Clinical Phenotype, Genotype and Therapy 143
Buffy coat-derived platelets cryopreserved using a new method: Results from a pivotal clinical trial on thrombocytopenic patients with acute leukaemia 143
Cancer patients requiring interruption of long-term warfarin because of surgery or chemotherapy induced thrombocytopenia: the use of fixed sub-therapeutic doses of low-molecular weight heparin. 142
Erythrocyte deformability and hemorheological profile in multiple myeloma 142
The risk of recurrent cardiovascular events in patients with increased plasma homocysteine levels is reduced by short but not long-term therapy with folate and B vitamins. 136
Patients requiring interruption of long-term oral anticoagulant therapy: the use of fixed sub-therapeutic doses of low-molecular-weight heparin 134
Buffy coat-derived platelets cryopreserved using a new method: Results from in vitro studies 134
Splenomegaly impacts prognosis in essential thrombocythemia and polycythemia vera: A single center study 134
Driver mutations and differential sensitivity to targeted therapies: a new approach to the treatment of lung adenocarcinoma 133
Italian Registry of Haemophilia and Allied Disorders. Objectives, methodology and data analysis 132
Bone marrow characteristics predict outcome in a multicenter cohort of primary immune thrombocytopenia patients treated with thrombopoietin analogues 132
Extracellular vesicle microRNAs contribute to the osteogenic inhibition of mesenchymal stem cells in multiple myeloma 131
Quality of Life in Patients With Cancer Under Prolonged Anticoagulation for High-Risk Deep Vein Thrombosis: a Long-Term Follow-Up 131
Relapsing or refractory idiopathic thrombotic thrombocytopenic purpura-hemolytic uremic syndrome: the role of rituximab. 130
Cardio-oncology in multiple myeloma: is it time for a specific focus? 129
Tailoring haemophilia A prophylaxis with BAY 81-8973: A case series 129
Aspirin for preventing the recurrence of venous thromboembolism 128
Long term outcomes of patients with cerebral vein thrombosis: a multicenter study. 128
Recurrent venous thromboembolism complicated by heparin-induced thrombocytopenia as a first manifestation of an occult cancer: a case report. 127
Clinical implications of discordant early molecular responses in CML patients treated with imatinib 127
Combined Point of Care Tools Are Able to Improve Treatment Adherence and Health-Related Quality of Life in Patients with Severe Hemophilia: An Observational Prospective Study 126
Hematopoietic Peripheral Circulating Blood Stem Cells As an Independent Marker of Good Transfusion Management in Patients with Beta-Thalassemia 124
CARDIOVASCULAR RISK IN ESSENTIAL THROMBOCYTHEMIA AND POLYCYTHEMIA VERA: THROMBOTIC RISK AND SURVIVAL 124
Efficacy and safety during formulation switch of a pasteurized VWF/FVIII concentrate: results from an Italian prospective observational study in patients with von Willebrand disease 123
Abdominal aortic thrombosis secondary to reactive thrombocytosis in a patient with iron deficiency anemia 122
Drug-Related Cardiotoxicity for the Treatment of Haematological Malignancies in Elderly. 120
Residual vein thrombosis and D-dimer for optimizing duration of anticoagulation in idiopathic deep vein thrombosis. 119
Demographic and clinical data in acquired hemophilia A: results from the European Acquired Haemophilia Registry (EACH2) 119
Superficial venous thrombosis: Prevalence of common genetic risk factors and their role on spreading to deep veins 118
Future directions in acquired hemophilia A 118
Refined cytogenetic-risk categorization for overall and leukemia-free survival in primary myelofibrosis: a single center study of 433 patients. 116
Peri-operative bridgning therapy with low molecular weight heparin in patients requiring interruption of long-term oral anticoagulant therapy 115
Coronary artery stenosis treatment in aging patients with inherited Factor VII deficiency: Where do we stand? 115
Red blood cell deformability in multiple myeloma 115
Trisomy 11: prevalence among 22 403 unique patient cytogenetic studies and clinical correlates. 114
Low dose of aPCC after the initial treatment in acquired haemophilia A is useful to reduce bleeding relapses: Data from the FAIR registry 114
Status of Recombinant Factor VIII Concentrate Treatment for Hemophilia a in Italy: Characteristics and Clinical Benefits 114
Emotions and Opinions of Adult Patients with Haemophilia During the COVID-19 (Coronavirus Disease 2019) Pandemic Caused by SARS-CoV-2: A Monocentric Survey 113
Deferral of assessment of pulmonary embolism 112
Management of Venous ThromboEmbolism in patients with acute leukemia at high bleeding risk: a multicenter study 112
Combined use of antifibrinolytics and activated prothrombin complex concentrate (aPCC) is not related to thromboembolic events in patients with acquired haemophilia A: data from FAIR Registry 112
BCR-ABL1 doubling-times and halving-times may predict CML response to tyrosine kinase inhibitors 111
Acquired Hemophilia A Associated with Venous Thrombosis and Very High Inhibitor Titer: A Challenging Scenario 111
The Persistance of Residual Vein Thrombosis, after an Episode of Deep Vein Thrombosis, and the Risk of New Overt Cancer and Cardiovascular Disease 110
Lymphomas and thyroid: Bridging the gap 109
Can we compare haemophilia carriers with clotting factor deficiency to male patients with mild haemophilia? 109
Evaluation of Bone Marrow CD8+ tissue-Resident Memory T Cells in Multiple Myeloma 109
Antimicrobial prophylaxis in patients with immune thrombocytopenia treated with rituximab: a retrospective multicenter analysis 108
Clinical experience with retrievable vena cava filters: results of a prospective observational multicenter study. 106
Low molecular weight heparins as antineoplastic agents. 106
Phase III studies on novel oral anticoagulants for stroke prevention in atrial fibrillation -a look beyond the excellent results 106
The new HFA/ICOS risk assessment tool to identify patients with chronic myeloid leukaemia at high risk of cardiotoxicity 106
Deep vein thrombosis and pulmonary embolism can be treated at home in cancer patients 105
The MASTER registry on venous thromboembolism: description of the study cohort. 105
Persistance of residual vein thrombosis after an episode of deep vein thrombosis of the lower limbs and the risk of new cancer and cardiovascular disease. 103
PERIOPERATIVE BRIDGING THERAPY WITH LOW MOLECULAR WEIGH HEPARIN IN PATIENTS REQUIRING INTERRUPTION OF LONG-TERM ORAL ANTICOAGULANT THERAPY 103
Residual vein thrombosis assessment estabilishes the optimal duration of oral anticoagulants in patients with idiopatic or provoked deep vein thrombosis 103
Managing bleeding complications in patients treated with the old and the new anticoagulants. 103
Trombosi portale mesenterica idiopatica in paziente con doppia mutazione eterozigote del gene C677T e del gene A1298C della MTHFR 103
Cardiovascular events and intensity of treatment in polycythemia vera. 103
Asymptomatic immunoglobulin light chain amyloidosis (AL) at the time of diagnostic bone marrow biopsy in newly diagnosed patients with multiple myeloma and smoldering myeloma. A series of 144 cases and a review of the literature 103
Deferment of objective assessment of deep vein thrombosis and pulmonary embolism without increased risk of thrombosis: a practical approach based on the pretest clinical model, D-dimer testing, and the use of low-molecular-weight heparins 102
Prevalence of renal failure and use of antithrombotic prophylaxis among medical inpatients at increased risk of venous thromboembolic events. 102
Incidence of venous thromboembolism in patients undergoing thoracotomy for lung cancer. 102
Thigh-length versus below-knee compression elastic stockings for prevention of the postthrombotic syndrome in patients with proximal-venous thrombosis: a randomized trial. 102
Using pharmacokinetics for tailoring prophylaxis in people with hemophilia switching between clotting factor products: A scoping review 101
Survival in young patients with intermediate/high-risk myelofibrosis: estimates derived from databases for non transplant patients. 100
Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism. 100
Cardiovascular Toxicity in Cancer Patients Treated with Tyrosine Kinase Inhibitors: A Real-World Single-Center Experience 100
Cardiovascular risk factor in MPN patients 100
Absence of Residual Vein Thrombosis after an Episode of Idiopathic Deep Vein Thrombosis: Short-Term Anticoagulation Is Safe. The "Extended Dacus Study". 99
Totale 13.719
Salva come PNG Salva come JPEG
Categoria #
all - tutte 103.931
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 103.931
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/20202.500 0 0 0 0 0 0 608 344 634 305 388 221
2020/20214.349 160 416 537 601 379 213 314 282 393 332 347 375
2021/20223.008 195 591 79 130 84 160 148 155 350 396 204 516
2022/20233.912 392 733 96 405 411 619 225 307 449 45 157 73
2023/20242.042 91 286 167 280 153 356 215 88 26 58 39 283
2024/20251.496 164 268 242 459 195 164 4 0 0 0 0 0
Totale 25.229